Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Public ClinicalTrials.gov record NCT01874353. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy
Study identification
- NCT ID
- NCT01874353
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- 327 participants
Conditions and interventions
Conditions
Interventions
- Olaparib 300mg tablets Drug
- Placebo to match olaparib 300mg Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 130 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 2, 2013
- Primary completion
- Sep 18, 2016
- Completion
- Dec 30, 2025
- Last update posted
- Aug 2, 2025
2013 – 2025
United States locations
- U.S. sites
- 16
- U.S. states
- 13
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | — | — |
| Palo Alto Foundation Medical Group | San Francisco | California | — | — |
| University of Colorado | Aurora | Colorado | — | — |
| The Hospital of Central Connecticut | New Britain | Connecticut | — | — |
| Gynecologic Cancer Center | Orlando | Florida | — | — |
| North Shore University | Evanston | Illinois | — | — |
| Greater Baltimore Medical Center | Baltimore | Maryland | — | — |
| Johns Hopkins | Baltimore | Maryland | — | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | — | — |
| Massachusetts General Hospital | Boston | Massachusetts | — | — |
| MD Anderson at Cooper Cancer Center | Voorhees Township | New Jersey | — | — |
| Womens Cancer Care Associates | Albany | New York | — | — |
| Winthrop Gynecologic Oncology Associates | Mineola | New York | — | — |
| OSU JamesCare at Mill Run | Hilliard | Ohio | — | — |
| Henry Joyce Cancer Clinic | Nashville | Tennessee | — | — |
| Aurora St Lukes Medical Center | Milwaukee | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 110 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01874353, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 2, 2025 · Synced May 14, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01874353 live on ClinicalTrials.gov.